VALIDOGEN (formerly VTU Technology) - well established and globally recognized contract research and technology licensing business in the field of peptide & protein production process development
VALIDOGEN has profound experience in the design of expression strains and bioprocesses for the production of a wide range of peptides and proteins for diverse applications serving customers from a variety of different industries. VALIDOGEN produces all types of recombinant peptides / proteins from cytokines, growth factors, hormones, serum proteins to fusion proteins (Fc-and albumin fusion), protein scaffolds, antibody fragments and vaccine antigens, enzymes or allergens.
Contract Research Projects
- Serving customers for 15 years
- Customers and applications in multiple industry sectors from all continents
- Projects with industry giants as well as start-up companies
Licenses & Tech Transfer
- Commercial licenses granted to licensees from different industry sectors
- Successful technology transfers – Scale-up to industrial scale
- Customer proteins produced using VALIDOGEN’s UNLOCK PICHIA technology for Phase I clinical studies
Advanced Technology Platform
- UNLOCK PICHIA - proprietary Pichia pastoris peptide/protein expression toolbox
- Proven and globally recognized cutting-edge technology platform
- Unmatched in terms of yield, development timelines, quality & safety
Intellectual Property
- Key patents protecting our technological leadership position
- Firm IP position, several patent families
- Freedom to operate
Development & Collaborations
- Non exclusive technology development with Boehringer Ingelheim
- Several academic collaborations
- Several B2B collaborations
Team & Facilities
- Highly skilled and experienced team
- Strong background in protein production and optimized workflows
- State of the art laboratory infrastructure and production equipment
→ Press Downloads
→ All downloads
